Ascendis Pharma A/S (ASND) Q3 2023 Earnings Results

Ascendis Pharma Misses on EPS, Stock Up 1.84%

Ascendis Pharma reported a larger-than-expected loss per share for Q3 2023, which typically raises concerns among investors. However, the stock reacted positively, gaining 1.84%. This increase may reflect investor optimism or a broader market trend, despite the disappointing EPS figure.

The print

Key numbers

Actual vs. consensus

Metric	Actual	Expected	Surprise
EPS	$-3.09	N/A	-17.45%
Revenue	N/A	N/A	N/A

Management

Management commentary

Tone: Unknown

No transcript is on record, and the analysis is based on numerical results only.

Ascendis Pharma Misses on EPS, Stock Up 1.84%

Key numbers

Management commentary

Ascendis Pharma A/S

More earnings this week

Ascendis Pharma Misses on EPS, Stock Up 1.84%

Key numbers

Management commentary